JCJason C. Crane

Jason C. Crane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jason C. Crane has a total of 181 co-authors. Here are the top co-authors by number of shared publications:

  • Sarah J. Nelson

    Surbeck Laboratory for Advanced Imaging, Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158-2330, USA

    8 shared publications
  • Daniel B. Vigneron

    Department of Radiology and Biomedical Imaging University of California San Francisco USA

    5 shared publications
  • Albert P. Chen

    Margaret Hart Surbeck Laboratory of Advanced Imaging, Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA

    4 shared publications
  • Duan Xu

    Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA

    3 shared publications
  • Eric T. Han

    GE Healthcare, ASL West, Menlo Park, CA 94025, USA

    3 shared publications
  • Esin Ozturk-Isik

    Boğaziçi University

    3 shared publications

Latest Publications

  • Open Access

    Impact of Metastatic Microenvironment on Physiology and Metabolism of Small Cell Neuroendocrine Prostate Cancer Patient-Derived Xenografts

    by Shubhangi Agarwal, Deepti Upadhyay, Jinny Sun, Emilie Decavel-Bueff, Robert A. Bok, Romelyn Delos Santos, Said Al Muzhahimi, Rosalie Nolley, Jason Crane, John Kurhanewicz, et al.

    Background: Potent androgen receptor pathway inhibitors induce small cell neuroendocrine prostate cancer (SCNC), a highly aggressive subtype of metastatic androgen deprivation-resistant prostate cancer (ARPC) with limited treatment options and poor survival rates. Patients with metastases in the liver have a poor prognosis relative to those with bone metastases alone. The mechanisms that underlie the different behavior of ARPC in bone vs. liver may involve factors intrinsic to the tumor cell, tumor microenvironment, and/or systemic factors, and identifying these factors is critical to improved diagnosis and treatment of SCNC. Metabolic reprogramming is a fundamental strategy of tumor cells to colonize and proliferate in microenvironments distinct from the primary site. Understanding the metabolic plasticity of cancer cells may reveal novel approaches to imaging and treating metastases more effectively. Methods: Using magnetic resonance (MR) imaging and spectroscopy, we interrogated the physiological and metabolic characteristics of SCNC patient-derived xenografts (PDXs) propagated in the bone and liver, and used correlative biochemical, immunohistochemical, and transcriptomic measures to understand the biological underpinnings of the observed imaging metrics. Results: We found that the influence of the microenvironment on physiologic measures using MRI was variable among PDXs. However, the MR measure of glycolytic capacity in the liver using hyperpolarized 13C pyruvic acid recapitulated the enzyme activity (lactate dehydrogenase), cofactor (nicotinamide adenine dinucleotide), and stable isotope measures of fractional enrichment of lactate. While in the bone, the congruence of the glycolytic components was lost and potentially weighted by the interaction of cancer cells with osteoclasts/osteoblasts. Conclusion: While there was little impact of microenvironmental factors on metabolism, the physiological measures (cellularity and perfusion) are highly variable and necessitate the use of combined hyperpolarized 13C MRI and multiparametric (anatomic, diffusion-, and perfusion- weighted) 1H MRI to better characterize pre-treatment tumor characteristics, which will be crucial to evaluate treatment response.

  • Top Cited Papers

    Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma

    by Shawn L. Hervey-Jumper, Yalan Zhang, Joanna J. Phillips, Ramin A. Morshed, Jacob S. Young, Lucie McCoy, Marisa Lafontaine, Tracy Luks, Simon Ammanuel, Sofia Kakaizada, et al.

    PURPOSE: In patients with diffuse low-grade glioma (LGG), the extent of surgical tumor resection (EOR) has a controversial role, in part because a randomized clinical trial with different levels of EOR is not feasible. METHODS: In a 20-year retrospective cohort of 392 patients with IDH-mutant grade 2 glioma, we analyzed the combined effects of volumetric EOR and molecular and clinical factors on overall survival (OS) and progression-free survival by recursive partitioning analysis. The OS results were validated in two external cohorts (n = 365). Propensity score analysis of the combined cohorts (n = 757) was used to mimic a randomized clinical trial with varying levels of EOR. RESULTS: Recursive partitioning analysis identified three survival risk groups. Median OS was shortest in two subsets of patients with astrocytoma: those with postoperative tumor volume (TV) > 4.6 mL and those with preoperative TV > 43.1 mL and postoperative TV ≤ 4.6 mL. Intermediate OS was seen in patients with astrocytoma who had chemotherapy with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL in addition to oligodendroglioma patients with either preoperative TV > 43.1 mL and residual TV ≤ 4.6 mL or postoperative residual volume > 4.6 mL. Longest OS was seen in astrocytoma patients with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL who received no chemotherapy and oligodendroglioma patients with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL. EOR ≥ 75% improved survival outcomes, as shown by propensity score analysis. CONCLUSION: Across both subtypes of LGG, EOR beginning at 75% improves OS while beginning at 80% improves progression-free survival. Nonetheless, maximal resection with preservation of neurological function remains the treatment goal. Our findings have implications for surgical strategies for LGGs, particularly oligodendroglioma. [Media: see text]


  • Improving the Automatic Classification of Brain MRI Acquisition Contrast with Machine Learning

    by Julia Cluceru, Janine M. Lupo, Yannet Interian, Riley Bove, Jason C. Crane

    Automated quantification of data acquired as part of an MRI exam requires identification of the specific acquisition of relevance to a particular analysis. This motivates the development of methods capable of reliably classifying MRI acquisitions according to their nominal contrast type, e.g., T1 weighted, T1 post-contrast, T2 weighted, T2-weighted FLAIR, proton-density weighted. Prior studies have investigated using imaging-based methods and DICOM metadata-based methods with success on cohorts of patients acquired as part of a clinical trial. This study compares the performance of these methods on heterogeneous clinical datasets acquired with many different scanners from many institutions. RF and CNN models were trained on metadata and pixel data, respectively. A combined RF model incorporated CNN logits from the pixel-based model together with metadata. Four cohorts were used for model development and evaluation: MS research (n = 11,106 series), MS clinical (n = 3244 series), glioma research (n = 612 series, test/validation only), and ADNI PTSD (n = 477 series, training only). Together, these cohorts represent a broad range of acquisition contexts (scanners, sequences, institutions) and subject pathologies. Pixel-based CNN and combined models achieved accuracies between 97 and 98% on the clinical MS cohort. Validation/test accuracies with the glioma cohort were 99.7% (metadata only) and 98.4 (CNN). Accurate and generalizable classification of MRI acquisition contrast types was demonstrated. Such methods are important for enabling automated data selection in high-throughput and big-data image analysis applications.


  • Open Access

    NIMG-44. INTEGRATING AUTOMATED LESION SEGMENTATIONS FROM SINGLE-IMAGES INTO ROUTINE CLINICAL WORKFLOW FOR VOLUMETRIC RESPONSE ASSESSMENT

    by Javier Villanueva-Meyer, Pablo Damasceno, Marisa LaFontaine, James Hawkins, Tracy Luks, Jason Crane, Janine Lupo

    Volume calculations have not been adopted into glioma response assessment due to lengthy times for manual definition and unreliable measures provided by automated algorithms. Relatively new artificial intelligence approaches such as convolutional neural networks have significantly improved lesion segmentation with performance accuracies >90%. However, their adoption into routine practice remains limited due to poor generalizability and failure rates approaching 25% when incorporated into clinical workflow. The latter can be attributed to 1) the requirement of four different types of anatomic images (T2, T2-FLAIR, T1 pre- and post-contrast); 2) cumbersome preprocessing including alignment, reformatting, and skull removal; and 3) the lack of a well-integrated clinical deployment system. The goal of this study was to demonstrate how simple modifications to a robust network coupled with an integrated workflow can provide reliable measures of tumor volume for real-time use in the reading room. Leveraging NVIDIA’s Clara-Train software and a molecularly diverse dataset of 400 labeled images for training, we modified a top-performing ensembled 2D-U-Net to require a single image-volume input (T2-FLAIR or post-contrast T1 for the T2-hyperintense or contrast-enhancing lesions) and deployed the results in the clinic to provide quantitative volumetrics. Inference was performed on a mix of image orientations without any reformatting or skull-stripping. Training on only 115 of our 400 datasets, we achieved Dice Coefficients of 90% and 81% overlap of our auto-segmented T2 and contrast-enhancing lesions with manual labels in our 25-patient validation cohort (11 enhancing), compared to 91% and 83% overlap with the original model that required four anatomic images to segment each lesion. Radiologists can view segmentations directly from PACS as contours or overlays and provide numerical feedback for model refinement. The workflow has been applied on 50 cases to date without any failures and can be easily shared for deployment on any clinical PACS.


  • Hyperpolarized 13C MRI data acquisition and analysis in prostate and brain at University of California, San Francisco

    by Jason C. Crane, Jeremy W. Gordon, Hsin‐Yu Chen, Adam W. Autry, Yan Li, Marram P. Olson, John Kurhanewicz, Daniel B. Vigneron, Peder E.Z. Larson, Duan Xu

    Based on the expanding set of applications for hyperpolarized carbon‐13 (HP‐13C) MRI, this work aims to communicate standardized methodology implemented at the University of California, San Francisco, as a primer for conducting reproducible metabolic imaging studies of the prostate and brain. Current state‐of‐the‐art HP‐13C acquisition, data processing/reconstruction and kinetic modeling approaches utilized in patient studies are presented together with the rationale underpinning their usage. Organized around spectroscopic and imaging‐based methods, this guide provides an extensible framework for handling a variety of HP‐13C applications, which derives from two examples with dynamic acquisitions: 3D echo‐planar spectroscopic imaging of the human prostate and frequency‐specific 2D multislice echo‐planar imaging of the human brain. Details of sequence‐specific parameters and processing techniques contained in these examples should enable investigators to effectively tailor studies around individual‐use cases. Given the importance of clinical integration in improving the utility of HP exams, practical aspects of standardizing data formats for reconstruction, analysis and visualization are also addressed alongside open‐source software packages that enhance institutional interoperability and validation of methodology. To facilitate the adoption and further development of this methodology, example datasets and analysis pipelines have been made available in the supporting information.


  • Open Access

    Power estimation for non-standardized multisite studies

    by Anisha Keshavan, Friedemann Paul, Mona K. Beyer, Alyssa H. Zhu, Nico Papinutto, Russell T. Shinohara, William Stern, Michael Amann, Rohit Bakshi, Antje Bischof, et al.


  • Strategies for rapid in vivo 1H and hyperpolarized 13C MR spectroscopic imaging

    by Sarah J. Nelson, Eugene Ozhinsky, Yan Li, Il Woo Park, Jason Crane


  • Open Access

    SIVIC: Open-Source, Standards-Based Software for DICOM MR Spectroscopy Workflows

    by Jason C. Crane, Marram P. Olson, Sarah J. Nelson

    Quantitative analysis of magnetic resonance spectroscopic imaging (MRSI) data provides maps of metabolic parameters that show promise for improving medical diagnosis and therapeutic monitoring. While anatomical images are routinely reconstructed on the scanner, formatted using the DICOM standard, and interpreted using PACS workstations, this is not the case for MRSI data. The evaluation of MRSI data is made more complex because files are typically encoded with vendor-specific file formats and there is a lack of standardized tools for reconstruction, processing, and visualization. SIVIC is a flexible open-source software framework and application suite that enables a complete scanner-to-PACS workflow for evaluation and interpretation of MRSI data. It supports conversion of vendor-specific formats into the DICOM MR spectroscopy (MRS) standard, provides modular and extensible reconstruction and analysis pipelines, and provides tools to support the unique visualization requirements associated with such data. Workflows are presented which demonstrate the routine use of SIVIC to support the acquisition, analysis, and delivery to PACS of clinical1H MRSI datasets at UCSF.


  • Prospective image registration for automated scan prescription of follow-up knee images in quantitative studies

    by Janet Goldenstein, Joseph Schooler, Jason C. Crane, Eugene Ozhinsky, Jean-Baptiste Pialat, Julio Carballido-Gamio, Sharmila Majumdar


  • Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme

    by Y. Li, J. M. Lupo, M.-Y. Polley, J. C. Crane, W. Bian, S. Cha, S. Chang, S. J. Nelson

    The objective of this study was to test the predictive value of serial MRI data in relation to clinical outcome for patients with glioblastoma multiforme (GBM). Sixty-four patients with newly diagnosed GBM underwent conventional MRI and diffusion-weighted and perfusion-weighted imaging postsurgery and prior to radiation/chemotherapy (pre-RT), immediately after RT (post-RT), and every 1-2 months thereafter until tumor progression, up to a maximum of 1 year. Tumor volumes and perfusion and diffusion parameters were calculated and subject to time-independent and time-dependent Cox proportional hazards models that were adjusted for age and MR scanner field strength. Larger volumes of the T2 hyperintensity lesion (T2ALL) and nonenhancing lesion (NEL) at pre-RT, as well as increased anatomic volumes at post-RT, were associated with worse overall survival (OS). Higher normalized cerebral blood volumes (nCBVs), normalized peak height (nPH) and normalized recirculation factors (nRF) at pre-RT, and nCBV at post-RT, in the T2ALL and NEL, were associated with shorter progression-free survival (PFS). From pre- to post-RT, there was a reduction in nCBV and nPH and an increase in apparent diffusion coefficient (ADC). Patients with lower nRF values at pre-RT, or a larger increase in nRF from pre-RT to post-RT, had significantly longer PFS. Time-dependent analysis showed that patterns of changes in ADC and anatomic volumes were associated with OS, while changes in nCBV, nPH, and the contrast-enhancing volume were associated with PFS. Our studies suggest that quantitative MRI variables derived from anatomic and physiological MRI provide useful information for predicting outcome in patients with GBM.